FDA’s Proposed Name Review Pilot Offers Little Reason To Participate

A proposed FDA pilot program that would shift the burden for safety review of proprietary drug names from the agency to industry needs to account for key differences between OTC and Rx products and lacks participation incentives, pharmaceutical researchers say